Piper Sandler has recently initiated Procept Biorobotics Corp (PRCT) stock to Overweight rating, as announced on August 11, 2023, according to Finviz. Earlier, on May 31, 2023, William Blair had initiated the stock to Outperform. BTIG Research also initiated Neutral rating. Additionally, Truist initiated Buy rating on October 25, 2022, with a target price of $58. Wells Fargo analysts, in their report published on September 2, 2022, also initiated Overweight rating and set a price target of $49 for Procept Biorobotics Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Procept Biorobotics Corp (PRCT) Stock Trading Recap
On Tuesday, Procept Biorobotics Corp (PRCT) stock saw a decline, ending the day at $76.2 which represents a decrease of $-3.92 or -4.89% from the prior close of $80.12. The stock opened at $79.48 and touched a low of $73.38 during the day, reaching a high of $79.58. The volume of shares traded was 1.01 million exceeding the average volume of 0.66 million.
PRCT Stock Performance and Moving Averages
In recent trading, Procept Biorobotics Corp (PRCT) stock price has shown some volatility, fluctuating -3.92% over the last five trades and -3.54% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 63.66%, and it has gained 20.65% in the previous three months. Currently, PRCT is trading at -4.02%, 5.28%, and 30.23% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, PRCT, a Healthcare sector stock, is trading -11.20% below its 52-week high but remains 206.89% above its 52-week low. The Average True Range (ATR) (14 days) of 3.73 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Procept Biorobotics Corp’s Profitability and Valuation Ratios
Procept Biorobotics Corp’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -62.09% and a profit margin of -58.73%, with a gross margin of 63.66%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Procept Biorobotics Corp’s market capitalization stands at $3.96 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 22.41, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 15.71, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 5.74% of Procept Biorobotics Corp (PRCT)’s shares, while financial institutions hold 84.67%.
Notable insider trades include Waters Kevin, EVP, CFO at Procept Biorobotics Corp (PRCT), who sold 25000 shares on Sep 16 ’24, at $82.51 each, totaling $2.06 million. On Sep 12 ’24, Desai Antal Rohit, Director, sold 44867 shares for $80.11 each, amounting to $3.59 million. Additionally, on Sep 11 ’24, Desai Antal Rohit sold 38698 shares at $77.54 each, generating $3.00 million.
